MT-1 (Melanotan 1)

Scientific Background and Research Context

Melanotan I, also known as MT-1 or afamelanotide, is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH). It is part of the melanocortin peptide family and is mainly studied for its interaction with the melanocortin-1 receptor (MC1R), a receptor found on melanocytes that plays a central role in melanin production and skin pigmentation.

MT-1 attracted scientific interest because α-MSH is a natural signalling peptide involved in pigmentation biology. When α-MSH activates MC1R on melanocytes, it can increase production of eumelanin, the darker form of melanin associated with photoprotective pigmentation. Researchers became interested in MT-1 because it was designed to produce stronger and longer-lasting melanocortin signalling than natural α-MSH.

This made MT-1 relevant to research areas such as:

• melanocyte biology
• pigmentation pathways
• photoprotection research
• MC1R receptor signalling
• UV-response mechanisms
• erythropoietic protoporphyria research
• dermatology and pigment-cell science

Exploring the Science Behind MC1R

The central mechanism of MT-1 research is its activity at the MC1R pathway. MC1R activation influences melanogenesis, the biological process by which melanocytes produce and distribute melanin. Increased eumelanin production is scientifically important because eumelanin absorbs and scatters ultraviolet radiation more effectively than lighter pigment types.

Research into MC1R agonists therefore helps scientists understand how pigmentation, UV sensitivity, oxidative stress, and phototoxic reactions are connected. Reviews describe afamelanotide as a synthetic α-MSH analogue that binds MC1R and enhances eumelanin production.

Research Context in Photoprotection and Dermatology

MT-1 has been studied most prominently in relation to photosensitivity disorders, especially erythropoietic protoporphyria (EPP). EPP is a rare condition in which light exposure can trigger painful phototoxic reactions. Afamelanotide, the pharmaceutical form of Melanotan I, has been developed as an implant for this specific medical context.

In the United States, SCENESSE®, an afamelanotide implant, is FDA-approved to increase pain-free light exposure in adults with a history of phototoxic reactions from EPP. This approval applies to that regulated prescription implant and indication, not to cosmetic tanning products or unregulated Melanotan products.

Difference Between Melanotan I and Melanotan II

Melanotan I and Melanotan II are often discussed together, but they are not the same compound. MT-1 / afamelanotide is more closely associated with MC1R-focused pigmentation and photoprotection research. Melanotan II is a different α-MSH analogue with broader melanocortin receptor activity and is commonly discussed in relation to unregulated tanning use and a different side-effect profile. Current dermatology reporting and scientific literature caution that cosmetic or unregulated melanotan use is not the same as an approved medical product.

Ongoing Scientific Interest

MT-1 remains important in research because it provides a way to study how melanocortin signalling affects pigmentation, phototoxicity, UV sensitivity, and skin-protective pathways. It is also a useful reference compound for understanding how synthetic peptide analogues can be modified to improve receptor activity and biological duration.

Overall, MT-1 / Melanotan I is best understood as a melanocortin research peptide connected to MC1R activation, eumelanin production, photoprotection, and pigment-cell biology.

For research and laboratory use only. Not for human or veterinary use.